Spinal muscular atrophy (SMA) is an autosomal recessive genetic disorder caused by a defect in the SMN1 gene on chromosome 5q. Its core manifestations are degeneration of anterior horn motor neurons in the spinal cord and progressive muscle weakness and atrophy. It is the leading cause of death among children under 2 years old, but can also affect children, adolescents, and adults.

Due to the loss of SMN1 gene function, patients are unable to synthesize sufficient survival motor neuron protein (SMN), leading to continuous apoptosis of motor neurons. SMN2, as a homologous backup gene, can only produce about 10% of the functional full-length SMN protein, insufficient to compensate for the defect. Clinically, there is an urgent need for drugs that target the root cause, are highly accessible, and suitable for long-term home treatment. The legitimate distribution and stable supply of these drugs are crucial in connecting patients with treatment plans, which is precisely the core value of professional pharmaceutical distributors like DengYueMed.

I. Core Mechanism of Action of Lispritz Tablets

Lispritz is an SMN2 pre-mRNA splicing modifier that acts directly on the root cause of the disease:

It precisely regulates SMN2 gene splicing, promotes exon 7 retention, and significantly increases the production of full-length functional SMN protein;

It can penetrate the blood-brain barrier, achieving central and peripheral systemic distribution, simultaneously protecting central motor neurons and peripheral muscle function;

It is administered orally as a small molecule once daily, continuously maintaining protein levels and preventing motor neuron degeneration.

II. Indications and Applicable Population Lispritz tablets are indicated for all types of SMA patients aged 16 days and older, covering:

Infantile SMA (Type I)

Late-onset SMA (Types II and III)

Presymptomatic SMA diagnosed by newborn screening

III. Core Advantages of Tablet Formulation (Compared to Oral Solution)

More Stable Storage: The 5mg tablet can be stored at room temperature without cold chain, reducing transportation and home management risks;

Easier Administration: Can be swallowed whole or dispersed in water, without the need for meals or professional preparation;

Higher Adherence: Precise dosage, easy to carry, suitable for long-term daily treatment, enhancing patient self-medication and dignity;

More Comprehensive Coverage: The standard dose for patients aged 2 years and older and weighing ≥20kg is 5mg daily, while patients weighing <20kg are given 0.25mg/kg.

IV. Key Clinical Efficacy Data

Pre-symptomatic Intervention: Treatment initiated within 6 weeks of age resulted in 100% of infants being able to sit independently and 92% being able to walk independently, approaching the motor milestones of healthy children, with no need for permanent ventilation;

Infantile SMA: Significantly improved motor function, reduced the risk of respiratory and feeding complications, and prolonged event-free survival;

Type II SMA: After 12 months of treatment, the average HFMSE motor score improved by 3.0 points, reversing the natural decline trend;

Type III SMA: The annualized rate of motor function decline slowed by 58%, significantly delaying the loss of walking ability;

Adult SMA: 3 years of real-world data confirmed stable motor function, maintained respiratory function, and continuous improvement in upper limb function.

V. Safety and Adverse Reactions

Overall safety is good, with most adverse reactions being mild to moderate, manageable, and reversible:

Common: fever, diarrhea, rash, upper respiratory tract infection, constipation, vomiting;

Infant patients require close monitoring for respiratory infections and pneumonia;

Contraindications: Contraindicated in patients with hypersensitivity to liximab or excipients;

Special Populations: Avoid use in patients with hepatic impairment;

Men and women of childbearing age should strictly practice contraception during treatment and for ≥1 month after discontinuation;

Pregnant and lactating women require strict assessment of benefit and risk.

Conclusion

Liximab tablets, with their precise molecular mechanism, universal indications, convenient oral formulation, and reliable long-term efficacy, have become a core choice for the corrective treatment of SMA. The tablet market further optimizes accessibility and user experience, driving the transformation of SMA from a "rare severe disease" to a "manageable chronic disease," providing crucial support for preserving motor function, improving quality of life, and extending survival.

This initiative aims to transform SMA from a "rare severe illness" to a "chronic disease that can be managed in the long term." DengYueMed, as one of China's leading pharmaceutical distributors, leverages its formal qualifications, comprehensive supply chain system, and professional services to become a vital bridge connecting Lisperan tablets with patients, effectively addressing the pain points of "difficulty in accessing medication" and "long distance to obtain medication."